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In earlier studies, we reported that a heterologous prime-boost regimen using recombinant plasmid DNA followed by replication-
defective adenovirus vector, both containingTrypanosoma cruzi genes encoding trans-sialidase (TS) and amastigote surface protein
(ASP) 2, provided protective immunity against experimental infectionwith a reticulotropic strain of this human protozoan parasite.
Herein, we tested the outcome of genetic vaccination of F1 (CB10XBALB/c) mice challenged with myotropic parasite strains (Brazil
and Colombian). Initially, we determined that the coadministration during priming of a DNA plasmid containing the murine IL-12
gene improved the immune response and was essential for protective immunity elicited by the heterologous prime-boost regimen
in susceptible male mice against acute lethal infections with these parasites.The prophylactic or therapeutic vaccination of resistant
female mice led to a drastic reduction in the number of inflammatory infiltrates in cardiac and skeletal muscles during the chronic
phase of infection with either strain. Analysis of the electrocardiographic parameters showed that prophylactic vaccination reduced
the frequencies of sinus arrhythmia and atrioventricular block. Our results confirmed that prophylactic vaccination using the TS
and ASP-2 genes benefits the host against acute and chronic pathologies caused by T. cruzi and should be further evaluated for the
development of a veterinary or human vaccine against Chagas disease.
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1. Introduction
Chagas disease is an acute and chronic illness caused by
Trypanosoma cruzi, an obligatory intracellular protozoan
parasite that is endemic in the Americas. The disease cur-
rently affects millions of people who are chronically infected.
Thousands of new cases are also estimated to occur every
year [1, 2]. Prophylactic measures aimed at eliminating
transmission by the vector (kissing bugs) have been very
successful in many countries [3]. Considering their success
and the highly neglected state of Chagas disease research,
vaccine development has often been considered a difficult and
expensive strategy for disease control and eradication.
Despite this general consideration, recent theoretical
studies have shown a divergent perspective on the prob-
lem, indicating that the development of a vaccine against
Chagas disease would be cost effective even if the efficacy
is not high and the transmission is low [4, 5]. In moving
toward the development of vaccines against Chagas disease,
several laboratories have described a number of antigens
and delivery systems capable of providing some degree of
protective immunity against experimental infections. These
systems include genetically attenuated parasites, recombi-
nant protein in adjuvant systems, and genetically modified
bacteria or viral vectors (reviewed in [6–12]). The antigens
pursued for recombinant vaccines include T. cruzi trans-
sialidase, cruzain (a cysteine proteinase), and the amastigote
surface proteins 2, 3, 4, TcG1, TcG2, TcG4, TSA-1, and Tc24
(reviewed in [6–12]).
Our group in particular has been working for many years
on the development of genetic vaccines against T. cruzi infec-
tion.We initially used the gene encoding the catalytic domain
of the parasite trans-sialidase (TS, [13, 14]). More recently,
we have described studies using a heterologous prime-boost
regimen consisting of priming with plasmid DNA followed
by a booster injection with replication-defective recombinant
human adenovirus type 5. Both the prime and the boost
contained the gene encoding the amastigote surface pro-
tein (ASP)-2 antigen of T. cruzi. This regimen successfully
vaccinated highly susceptible A/Sn and resistant C57BL/6
mice against infection with the reticulotropic Y strain of T.
cruzi [15–18]. Protective immunity was mediated by long-
lived CD4+ and CD8+ T Effector or effector memory cells
[15, 19, 20].
T. cruzi infection in mammalian hosts leads to diverse
clinical manifestations. Among the most relevant factors
influencing this diversity is the existence of biologically dif-
ferent parasite strains.T. cruzi intraspecific nomenclaturewas
established in 2009, and the isolates and strains are assigned
to one of six genetic groups or discrete typing units, named
TcI to TcVI [21]. Among domestic transmission cycles, TcI
occurs predominantly in northern SouthAmerica, while TcII,
TcV, and TcVI are more often observed in the Southern
Cone countries [22]. Considering this genetic variability, it
is important that studies of vaccination or chemotherapy are
conducted in different experimental models using distinct
parasite strains. Because our previous studies of vaccination
have been performedwith the reticulotropic Y strain (TcII), it
was our intention to extend these studies using experimental
infections with twomyotropic strains of the parasites belong-
ing to TcI (Colombian) and TcII (Brazil).
2. Materials and Methods
2.1. Ethics Statement. This study was carried out in strict
accordance with the recommendations in the Guide for the
Care andUse of LaboratoryAnimals of the BrazilianNational
Council of Animal Experimentation (http://www.cobea.org
.br/). The protocol was approved by the Committee on the
Ethics of Animal Experiments of the Institutional Animal
Care and Use Committee at the Federal University of Sao
Paulo (Id # CEP 0426/09).
2.2. Mice and Parasites. Female or male 5- to 8-week-old F1
(CB10XBALB/c) mice were purchased from CEDEME (Fed-
eral University of Sa˜o Paulo). Bloodstream trypomastigotes
of the Colombian or Brazil strain of T. cruzi were obtained
from mice infected 21–28 days earlier. The concentration of
parasites was estimated and adjusted to 104 parasites/mL.
Each mouse was inoculated with 103 trypomastigotes diluted
in 0.1mL PBS and administrated subcutaneously (s.c.) in the
base of the tail.
2.3. Peptides. Synthetic peptides (Genscript, Piscataway, New
Jersey) were higher than 90% pure. The immunodominant
epitopes of ASP-2 or TSwere represented byAAVNHRFTLV
or IYNVGQSVI, respectively.
2.4. Genetic Vaccination. The plasmid (pWRG3169) contain-
ing coding sequences for the p35 and p40 subunits of murine
(m) IL-12 was generated as earlier described [23]. Plasmids
p154/13 (TS gene) or pIgSPclone9 (ASP-2 gene) were gen-
erated, grown, and purified as described earlier [13, 24].
Human replication deficient adenovirus type 5 expressing the
ASP-2 gene (AdASP-2) or TS gene (AdTS) was generated
and produced as described earlier [25] Control mice were
immunized with pcDNA3 and human replication deficient
adenovirus type 5 expressing 𝛽-galactosidase (Ad𝛽-gal). F1
(CB10XBALB/c) mice were immunized i.m. in each tibialis
anterioris muscle with plasmid DNA. For priming, control
mice received plasmid pcDNA3 (300 𝜇g), a second group
was immunized with a mixture of pIgSPCl9 and p154/13
(200𝜇g), and the third, a mixture of pIL12, pIgSPCl9, and
p154/13 (300 𝜇g). Twenty-one days later, these mice received
in these same spots 100 𝜇L of viral suspension containing a
total of 2 × 108 plaque forming units (pfu) of rec. adenovirus.
For boosting, control mice received adenovirus Ad𝛽gal;
other mouse groups were immunized with a mixture of rec.
adenovirus AdASP-2 and Ad-TS. Immunological assays were
performed 14 days after viral inoculation.
Therapeutic vaccination was performed as follows. F1
(CB10XBALB/c) female mice were challenged s.c. with 1,000
trypomastigotes of the indicated parasite strain. Thirty days
later, control mice received a mixture of plasmid pcDNA3
and of pIL12 (300 𝜇g) and secondmice groupwas immunized
with a mixture of pIL12pIgSPCl9 and p154/13 (300 𝜇g).
Twenty days later, these mice received in these same spots
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100 𝜇L of viral suspension containing a total of 2 × 108 pfu
of rec. adenovirus. For boosting, control mice received
adenovirus Ad𝛽gal and the other mice were immunized with
a mixture of rec. adenovirus AdASP-2 and Ad-TS.
2.5. Immunological Assays. For the surface intracellular
expression of cytokines (IFN𝛾 and TNF, ICS) or translocation
of CD107a to the membrane, splenocytes collected from
immune mice were treated with ACK buffer. ICS and surface
mobilization of CD107a were evaluated after in vitro culture
of splenocytes in the presence or absence of the antigenic
stimulus. Cells were washed 3 times in plain RPMI and
resuspended in cell culture medium consisting of RPMI
1640 medium, pH 7.4, supplemented with 10mM Hepes,
0.2% sodium bicarbonate, 59mg/L of penicillin, 133mg/L of
streptomycin, and 10% Hyclone fetal bovine sera (Hyclone,
Logan, Utah). The viability of the cells was evaluated using
0.2% trypan blue exclusion dye to discriminate between live
and dead cells. Cell concentration was adjusted to 5 × 106
cells/mL in cell culture medium containing FITC-labeled
anti-CD107a (2 𝜇g/mL), anti-CD28 (2 𝜇g/mL), BdGolgiPlug,
and monensin (5 𝜇g/mL). In part of the cultures, a final
concentration of 10𝜇M of the VNHRFTLV or IYNVGQSVI
peptides was added. The cells were cultivated in flat-bottom
96-well plates (Corning) in a final volume of 200𝜇L in
duplicate, at 37∘C in a humid environment containing 5%
CO
2
. After 12 h incubation, cells were stained for surface
markers with PerCP-labeled anti-CD8, on ice for 20min. To
detect IFN𝛾 and TNF by intracellular staining, cells were
then washed twice in buffer containing PBS, 0.5% BSA, and
2mM EDTA, fixed and permeabilized with BD perm/wash
buffer. After being washed twice with BD perm/wash buffer,
cells were stained for intracellular markers using APC-
labeled anti-IFN𝛾 (Clone XMG1.2) and PE-labeled anti-TNF
(clone MP6-XT22). Finally, cells were washed twice with BD
perm/wash buffer and fixed in 1% PBS-paraformaldehyde. At
least 300,000 cells were acquired on a BD FacsCanto flow
cytometer and then analyzed with FlowJo.
2.6. Electrocardiogram (ECG). Mice were i.p. tranquilized
with diazepan (20mg/kg) and transducers were carefully
placed under the skin in accordance with chosen preferential
derivation (DII). Traces were recorded using a digital system
(Power Lab 2/20) connected to a bioamplifier in 2mV for 1 s
(PanLab Instruments). Filters were standardized between 0.1
and 100Hz and traces were analyzed using the Scope software
for Windows V3.6.10 (PanLab Instruments). We measured
heart rate (beats perminute—bpm), duration of the PR, QRS,
and QT intervals, and P wave in ms (millisecond) on 222 dpi.
The relationship between the QT interval and RR interval
was individually assessed to obtain physiologically relevant
values for the heart rate-correctedQT interval (QTc) through
Bazzet’s formula.
2.7.Morphometric Analyses. Analyses were performed essen-
tially as described in [26]. Briefly, heart sections were ana-
lyzed by light microscopy after paraffin embedding, followed
by standard hematoxylin and eosin staining. Inflammatory
cells infiltrating heart tissuewere counted using a digitalmor-
phometric evaluation system. Images were digitized using a
color digital video camera (CoolSnap, Photometrics, Mon-
treal, QC, Canada) adapted to a BX41 microscope (Olympus,
Tokyo, Japan). Morphometric analyses were performed using
the software Image-Pro Plus v.7.0 (Media Cybernetics¸ San
Diego, CA, USA). The inflammatory cells were counted in 10
fields (×400 view)/heart. All of the analyses were performed
in a blinded fashion.
2.8. Statistical Analysis. For the purpose of comparing the
different mouse groups, we used the statistical analyses
suggested by [27]. The values were compared using One
Way ANOVA followed by Tukey’s HSD tests or Fisher exact
probability test (http://faculty.vassar.edu/lowry/VassarStats
.html/). The Logrank test was used to compare mouse sur-
vival rates after challenge withT. cruzi (http://bioinf.wehi.edu
.au/software/russell/logrank/). The differences were consid-
ered significant when the 𝑃 value was <0.05.
3. Results
3.1. Addition of pIL-12 during Priming Improved the Immune
Response Mediated by CD8+ T Cells and Increased Pro-
tective Immunity against Acute Infection. A previous study
has reported that the coadministration of plasmid DNA
expressing IL-12 during priming improves the efficacy of a
heterologous prime-boost vaccination regimen, as estimated
by protective immunity against SIV infection [28]. We,
therefore, decided to determine whether this strategy could
also improve the immune response and protective immunity
against T. cruzi infection in the mouse model. Mice were
immunized with the following: (i) pcDNA3 followed by a
booster injection of Ad𝛽gal (G1, control); (ii) p154/13 and
pIgSPCl9 followed by a booster injection of AdASP-2 and
AdTS (G2); (iii) pIL-12, p154/13 and pIgSPCl9 followed by a
booster injection of AdASP-2 and AdTS (G3).
To compare the different mouse groups, we stained
CD8+ spleen cells following in vitro peptide stimulation for
the surface mobilization of CD107a, a marker for T cell
degranulation, and intracellular effector cytokines (IFN𝛾 and
TNF, ICS). Figure 1(a) depicts examples of the frequency
estimates of peptide-specificCD8+ spleen cells thatmobilized
CD107a to their surface and expressed IFN𝛾. The frequencies
of CD8+ cells that mobilized CD107a to the cell surface and
expressed IFN𝛾 were higher in G3. Control mice (G1) had
a negligible number of specific CD8+CD107a+IFN𝛾+ cells.
These frequencies were dependent on the presence of peptide
in culture because the frequency of CD8+CD107a+IFN𝛾+
cells was very small in the absence of peptide in all groups.
We made a similar observation when we estimated
the frequencies of splenic peptide-specific CD8 cells that
expressed IFN𝛾 or IFN𝛾 and TNF. These frequencies were
higher in G3 mice (Figure 1(b)). As described above, control
mice (G1) had a negligible number of specific CD8+IFN𝛾+
or CD8+IFN𝛾+TNF+ cells. The numerical differences and
the statistical significances are depicted in Figures 1(c)–
1(f). As shown in Figures 1(d) and 1(f), following peptide
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Figure 1: Continued.
Mediators of Inflammation 5
Magnitude
G3G2G1
0
2
4
6
8
10
12
G1 pcDNA3 Ad𝛽-gal
G2 p154/13+pIgSPCl.9 AdTS+AdASP2
G3 pIL12+p154/13+pIgSPCl.9 AdTS+AdASP2
Priming Boosting
CD
8
+
  ly
m
ph
oc
yt
es
 (%
)
∗
(e)
CD107a
TNF
+
−
−
−
+
−
−
−
+
+
+
−
+
−
+
−
+
+
+
+
+
IFN𝛾
0
1
2
3
4
5
CD
8
+
  ly
m
ph
oc
yt
es
 (%
)
∗
∗
∗
∗
G1 pcDNA3 Ad𝛽-gal
G2 p154/13+pIgSPCl.9 AdTS+AdASP2
G3 pIL12+p154/13+pIgSPCl.9 AdTS+AdASP2
Priming Boosting
(f)
Figure 1: Frequencies of specific cytokine-secreting splenic CD8+ T cells in mice vaccinated with the heterologous prime-boost vaccination
regimen. F1 (CB10XBALB/c) mice were immunized i.m. in each tibialis anteriormuscle with plasmid DNA. For priming, G1 received control
plasmid pcDNA3 (300 𝜇g), G2 was immunized with a mixture of pIgSPCl9 and p154/13 (200𝜇g), and G3 received a mixture of pIL-12,
pIgSPCl9, and p154/13 (300 𝜇g). Twenty-one days later, thesemice received, in these same spots, 100 𝜇L of a viral suspension containing a total
of 2 × 108 pfu of rec. adenovirus. For boosting, G1 received control adenovirus Ad𝛽gal, and G2 and G3 were immunized with a mixture of rec.
adenovirus AdASP-2 and Ad-TS. Immunological assays were performed 14 days after viral inoculation. Spleen cells were restimulated in vitro
in the presence or absence of the peptides VNHRFTLV or IYNVGQSVI, anti-CD107a, anti-CD28, BdGolgiPlug, and monensin. After 12 h,
the cells were stained with anti-CD8, anti-IFN𝛾, and anti-TNF. (a)The histograms show FACS analysis of CD8+ cells.The numbers represent
the frequencies of cells stained for CD107a and/or IFN𝛾. The results are a representative of 4 mice per group (Median). (b) Frequencies of
CD8+ cells stained for IFN𝛾 and/or TNF. The results are a representative of 4 mice per group (Median). (c) Total frequencies of CD8+ cells
specific for the peptide VNHRFTLV and stained for CD107a or IFN𝛾 or TNF. The results are representative of 4 mice per group (Mean ±
SD). (d) Frequencies of CD8+ cells specific for the peptide VNHRFTLV and stained for each marker (CD107a, IFN𝛾, or TNF). The results
are representative of 4 mice per group (Mean ± SD). (e) Same as in (c) for CD8+ cells specific for the peptide IYNVGQSVI. The results are
representative of 4 mice per group (Mean ± SD). (f) Same as in (d) for CD8+ cells specific for the peptide IYNVGQSVI. All three groups
were compared statistically by one-way ANOVA followed by Tukey HSD (c–e). The values of G2 and G3 mice were always higher than those
of G1 mice (𝑃 < 0.01 in all cases). Asterisks denote that the values of G3 mice were higher than those of G2 mice (𝑃 < 0.05). The results are
representative of three independent experiments.
stimulation in vitro, most of the CD8+ cells were either
CD107a+IFN𝛾+TNF+ or CD107a+IFN𝛾+.
To determine whether this improvement in the frequen-
cies of specific CD8+ T cells would impact protective immu-
nity, we vaccinated susceptible male mice and challenged
them with trypomastigotes of either the Brazil or Colombian
strain. As shown in Figures 2(a) and 2(c), mice vaccinated
with the TS and ASP-2 genes (G2 and G3) presented a
statistically significant reduction in peak parasitemia. A
comparison between these two groups also showed that
the parasitemia in G3 was significantly lower than that in
G2. Not only did mice from G3 display lower parasitemia,
but vaccination also significantly reduced mouse mortality
(Figures 2(b) and 2(d)). While all G3 mice survived the
experimental challenge, most control (G1) and G2 mice died
after challenge with the Brazil or Colombian parasite strain.
Based on these results, we concluded that the use of pIL-
12 for priming significantly improved the immune response
and the protective immunity against acute infection with the
myotropic Brazil and Colombian strains.
3.2. Impact of Genetic Vaccination against Chronic Infection.
To evaluate the impact of genetic vaccination on the chronic
symptoms of the experimental infection, resistant female
mice were treated according to the following protocols: (i)
na¨ıve (G1); (ii) pIL-12 and pcDNA3 followed by a booster
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Figure 2:The protective immunity elicited by heterologous prime-boost vaccination in susceptible mice. F1 (CB10XBALB/c) male mice were
immunized i.m. exactly as described in the legend of Figure 1. Fourteen days later, mice were challenged s.c. with 1,000 trypomastigotes of the
indicated parasite strain. (a) Mean parasitemia ± SD of each mouse group (𝑛 = 6) challenged with parasites of the Brazil strain. The values of
G2 and G3mice at days 21, 25 and 35 were lower than those of G1mice (𝑃 < 0.01 in all cases, one-way ANOVA, Tukey HSD). Asterisks denote
that the values of G3 mice were lower than those of G2 mice (𝑃 < 0.05); (b) The Kaplan-Meier survival curves of the different groups were
compared, and the results showed that G3 survived significantly longer (𝑃 < 0.01) than the two other groups; (c) Mean parasitemia ± SD of
each mouse group (𝑛 = 6) challenged with parasites of the Colombian strain.The values of G2 and G3 mice at days 25 and 31 were lower than
those of G1 mice (𝑃 < 0.01 in all cases). Asterisks denote that the values of G3 mice were lower than those of the G2 mice (𝑃 < 0.05); (d)The
Kaplan-Meier survival curves of the different groups were compared, and the results showed that G3 survived significantly longer (𝑃 < 0.01)
than the two other groups. The results were obtained from one of two independent experiments.
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Table 1: Summary of the ECG records.
Days after
challenge Strain
Sinus arrhythmia mouse groups 𝑃 values
G1 G2 G3 G1 × G2 G1 × G3 G2 × G3
80 Brazil 0/6 0/6 0/6 NS NS NS
150 Brazil 0/6 19/6 0/6 0.001 NS 0.001
240 Brazil 0/6 20/6 3/6 0.001 NS 0.026
80 Colombian 0/6 0/6 0/5 NS NS NS
150 Colombian 0/6 1/6 1/5 NS NS NS
240 Colombian 0/6 9/6 1/5 0.017 NS 0.093
Days after
challenge Strain
Atrioventricular block 𝑃 values
G1 G2 G3 G1 × G2 G1 × G3 G2 × G3
80 Brazil 0/6 0/6 0/6 NS NS NS
150 Brazil 0/6 4/6 2/6 0.03 NS NS
240 Brazil 0/6 59/6 7/6 0.001 0.004 0.003
80 Colombian 0/6 19/6 0/5 0.001 NS NS
150 Colombian 0/6 14/6 6/5 0.001 0.002 NS
240 Colombian 0/6 39/6 10/5 0.001 0.002 NS
ECG record of mice genetically vaccinated and challenged as described in the legend of Figure 5(a). Values represent the number of episodes (sinus arrhythmia
or atrioventricular block) recorded during one minute per total of mice analyzed and were compared by Fisher exact probability test.
injection of Ad𝛽gal (G2, control); (iii) pIL-12, p154/13 and
pIgSPCl9 followed by a booster injection of AdASP-2 and
AdTS (G3).
G2 and G3 mice were subsequently challenged with
parasites of either the Brazil or the Colombian strain, as
depicted in Figure 3(a). We estimated the level of parasitemia
for each mouse group. G3 mice presented a lower peak
parasitemia at day 27 (𝑃 = 0.02) after infection with
parasites of the Brazil strain (Figure 3(b)). In the case of mice
challenged with parasites of the Colombian strain, there was
a statistically significant reduction in the levels of parasitemia
at days 13, 20, 24, 28, and 31 (𝑃 < 0.05 in all cases, Figure 3(c)).
Individual ECGs were evaluated at days 80, 150, and
240 following infection. As shown in Table 1, the primary
abnormalities we detected were sinus arrhythmia and atri-
oventricular block. Significantly lower frequencies of sinus
arrhythmia were observed in G3 mice when compared with
G2 mice following infection with the Brazil or Colombian
strains. These differences were observed at later days (150 or
240 days) following challenge. Similarly, significantly lower
frequencies of atrioventricular block were observed in G3
mice when compared with G2 mice following infection with
parasites of the Brazil strain. In the case of mice challenged
with parasites of the Colombian strain, the differences were
smaller and not statistically significant.
At day 240 after challenge, the mice were euthanized,
and morphometric analyses of the heart and skeletal muscle
were performed. The number of inflammatory cells within
the skeletal muscle, but not the heart, of G3 mice challenged
with parasites of the Brazil strain was significantly lower
(Figure 4(b)). In G3 mice challenged with parasites of the
Colombian strain, we found significantly lower numbers of
inflammatory cells within the skeletal muscle and heart when
compared to G2 mice (Figure 4(c)).
We then evaluated the impact of therapeutic genetic
vaccination on the chronic symptoms of experimental infec-
tion. Resistant female mice were infected and then treated
according to the protocols described in Figures 5(a) and
6(a). Mice received the following treatments: (i) pIL-12 and
pcDNA3 followed by a booster injection of Ad𝛽gal (G2,
control); (ii) pIL-12, p154/13 and pIgSPCl9 followed by a
booster injection of AdASP-2 and AdTS (G3).
The estimation of parasitemia until day 50 did not reveal
any difference between G2 or G3mice infected with parasites
of the Brazil or Colombian strains (Figures 5(b) and 5(c),
resp.). We concluded that the plasmid administration at day
30 after challenge did not elicit immunity that could reduce
the ongoing parasitemia. Individual ECGs were evaluated at
days 90, 120, 150, and 180 following infection. As shown in
Table 2, we detected differences in the frequencies of sinus
arrhythmia, but not atrioventricular block, in G3 mice when
compared with G2 mice following infection with the Brazil
strain of T. cruzi. However, this difference was observed
only on days 90 and 120. Later (150 and 180 days), G3
mice also developed sinus arrhythmia. G3 mice infected
with parasites of the Colombian strain had significantly
lower frequencies of sinus arrhythmia at days 120 and 180,
when G2 mice developed a significant number of events.
However, the occurrence of atrioventricular block in G3mice
was similar to that in G2. At day 180 after challenge, the
mice were euthanized, and morphometric analyses of the
heart and skeletal muscle were performed. The numbers of
inflammatory cells within the skeletal muscle and heart of G3
mice challenged with parasites of the Brazil or Colombian
strains were significantly lower than the frequencies in the
tissues of G2 mice (Figures 6(b) and 6(c), resp.).
4. Discussion
The present study evaluated the outcome of experimen-
tal infection with two myotropic T. cruzi strains in F1
(CB10XBALB/c) mice genetically vaccinated with TS and
ASP-2 following a heterologous DNA prime-adenovirus
boost regimen. Prophylactic vaccination reduced the acute
8 Mediators of Inflammation
Groups Prime Boost Challenge
pIL12+pcDNA3 Ad𝛽-gal T. cruzi
AdTS+AdASP-2 T. cruzipIL12+p154/13       
+pIgSPCL9
Plasmid
DNA
Rec. 
adenovirus
0 21 35
Days
Challenge
G2
G3
(a)
Days afer challenge
0 10 20 30 40 50 60 70 80
Pa
ra
sit
em
ia
 (l
og
)
3
4
5
6
Brazil
G2
G3
∗
(b)
Days after challenge
0 20 40 60 80 100
Pa
ra
sit
em
ia
 (l
og
)
3
4
5
6
7
Colombian
G2
G3
∗
∗
∗∗
∗
(c)
Figure 3: The protective immunity elicited by heterologous prime-boost vaccination in resistant mice. (a) F1 (CB10XBALB/c) female mice
were immunized i.m. as depicted. For priming, G2 mice received a mixture of control plasmid pcDNA3 and of pIL-12 (300 𝜇g), and G3 mice
were immunized with a mixture of pIL-12, pIgSPCl9 and p154/13 (300𝜇g). Twenty-one days later, these mice received, in these same spots,
100𝜇L of a viral suspension containing a total of 2 × 108 pfu of rec. adenovirus. For boosting, G2 mice received control adenovirus Ad𝛽gal,
and G3 mice were immunized with a mixture of rec. adenovirus AdASP-2 and Ad-TS. Fourteen days later, mice were challenged s.c. with
1,000 trypomastigotes of the indicated parasite strain. (b) Mean parasitemia ± SD of each mouse group (𝑛 = 6) challenged with parasites of
the Brazil strain. Asterisk denotes that at day 37, the values of G3 mice were lower than those of G2 mice (𝑃 < 0.05, one-way ANOVA, Tukey
HSD); (c) Mean parasitemia ± SD of each mouse group (𝑛 = 6) challenged with parasites of the Colombian strain. Asterisks denote that at
days 13 to 31, the values of G3 mice were lower than those of G2 mice (𝑃 < 0.05).
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Figure 4: Frequencies of inflammatory cells in the hearts and skeletal muscles of resistant mice vaccinated by the heterologous prime-boost
regimen. (a) F1 (CB10XBALB/c) female mice were immunized i.m., as depicted. Details on the dose are shown in Figure 3(a). (b) At 240
days, heart and skeletal muscle sections of mice challenged with the Brazil strain were stained with hematoxylin and eosin, and the number
of inflammatory cells was quantified. Bars represent the mean of 6 mice/group ± SD. Asterisks denote that there was a significant difference
between the indicated groups ( ∗𝑃 < 0.05 or ∗∗𝑃 < 0.01). (c) The same as above, except that the mice were challenged with parasites of the
Colombian strain. Bars represent the mean of 5 mice/group ± SD.
phase symptoms, as estimated by parasitemia and mortality.
In addition, ECG analysis demonstrated that prophylactic
vaccination also reduced some of the chronic phase signs.
These results essentially confirm and extend our previous
observations in mice challenged with a reticulotropic T. cruzi
strain [15–20].
In contrast to prophylactic vaccination, the therapeutic
use of our vaccine had a much lower impact on the chronic
phase signs evaluated by ECG. The treatment reduced sinus
arrhythmia earlier in mice challenged with the Brazil strain.
Additionally, most mice challenged with the Colombian
strain never developed episodes of sinus arrhythmia. Despite
this observation, no differences were detected in the fre-
quencies of episodes of atrioventricular block. It is important
to highlight that these ECG alterations occurred in mice
with a reduced number of inflammatory cells in their heart.
This dichotomy most likely reflects the successful control
by vaccination of the inflammatory reactions later during
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Figure 5: Impact of therapeutic vaccination in the immunity of resistant mice. (a) F1 (CB10XBALB/c) female mice were challenged s.c. with
1,000 trypomastigotes of the indicated parasite strain.Thirty days later, G2 mice received a mixture of control plasmid pcDNA3 and of pIL-12
(300 𝜇g), and G3 mice were immunized with a mixture of pIL-12, pIgSPCl9, and p154/13 (300𝜇g). Twenty days later, these mice received,
in these same spots, 100 𝜇L of a viral suspension containing a total of 2 × 108 pfu of rec. adenovirus. For boosting, G2 mice received control
adenovirus Ad𝛽gal, and G3mice were immunized with a mixture of rec. adenovirus AdASP-2 and Ad-TS. (b) Mean parasitemia ± SD of each
mouse group (𝑛 = 6) challenged with parasites of the Brazil strain. (c) Mean parasitemia ± SD of each mouse group (𝑛 = 6) challenged with
parasites of the Colombian strain.
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Figure 6: Frequencies of inflammatory cells in the hearts and skeletal muscles of resistant mice treated by the heterologous prime-boost
regimen. (a) F1 (CB10XBALB/c) female mice were immunized i.m., as depicted. Details on the dose are shown Figure 5(a). (b) At 180 days,
heart and skeletal muscle sections of mice challenged with the Brazil strain were stained with hematoxylin and eosin, and the number of
inflammatory cells was quantified. Bars represent the mean of 6 mice/group ± SD. Asterisks denote that there was a significant difference
between the indicated groups ( ∗𝑃 < 0.05 or ∗∗𝑃 < 0.01). (c) The same as above, except that the mice were challenged with parasites of the
Colombian strain.
infection, when the mice were euthanized. However, the
damage to the heart had been established earlier and could
no longer be reversed.
The reason why the T cells elicited by therapeutic genetic
vaccination are not capable of reducing the symptoms is
unknown at present. One possibility is that following infec-
tion, specific T cells are already committed to express the
death receptor CD95, as we have recently described [29].
Once these cells express CD95, their viability is impaired, and
they can no longer expand properly. It will be important to
test this possibility because it has implications for the use of
T cell vaccines for therapeutic purposes during this or other
chronic diseases [30–36].
Theprotective immunemechanismsmediating the effects
of our new vaccination regimen were not addressed in the
present study. However, it is plausible that CD4+ and CD8+
T cells participate in this immune response, as we have previ-
ously described [15]. Corroborating this hypothesis is the fact
that the addition of pIL-12 during priming led to a significant
increase in the frequencies of multifunctional CD8+ T cells
and a parallel increase in the protective immunity against
acute infection.
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Table 2: Summary of the ECG records.
Days after
challenge Strain
Sinus arrhythmia mouse groups 𝑃 values
G1 G2 G3 G1 × G2 G1 × G3 G2 × G3
90 Brazil 0/6 10/6 0/6 0.001 NS 0.012
120 Brazil 0/6 10/6 1/6 0.001 NS 0.044
150 Brazil 0/6 11/6 5/6 0.001 0.007 NS
180 Brazil 0/6 4/6 4/6 0.03 0.03 NS
90 Colombian 0/6 3/6 1/5 NS NS NS
120 Colombian 0/6 3/6 0/5 NS NS NS
150 Colombian 0/6 12/6 0/5 0.001 NS 0.013
180 Colombian 0/6 16/6 1/5 0.001 NS 0.022
Days after
challenge Strain
Atrioventricular block mouse groups 𝑃 values
G1 G2 G3 G1 × G2 G1 × G3 G2 × G3
90 Brazil 0/6 36/6 46/6 0.001 0.001 NS
120 Brazil 0/6 19/6 22/6 0.001 0.001 NS
150 Brazil 0/6 5/6 6/6 0.007 0.001 NS
180 Brazil 0/6 5/6 3/6 0.007 NS NS
90 Colombian 0/6 20/6 30/5 0.001 0.001 NS
120 Colombian 0/6 27/6 15/5 0.001 0.001 NS
150 Colombian 0/6 6/6 2/5 0.001 NS NS
180 Colombian 0/6 10/6 10/5 0.001 0.001 NS
ECG record of mice challenged and treated as described in the legend of Figure 6(a). Values represent the number of episodes (sinus arrhythmia or
atrioventricular block) recorded during one minute per total of mice analyzed and were compared by Fisher exact probability test.
In conclusion, this study reinforces and extends our
previous work by demonstrating the improvement in acute
and chronic symptoms after prophylactic genetic vaccination
against T. cruzi infection using a vector expressing the TS and
ASP-2 antigens.
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